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 ABSTRACT  
 
This paper examines the Revenue Recognition – Milestone Method (RRMM), 
FASB codification amendment of 2010 and its effect on the health of firms heavily 
dependent on the Research and Development (R&D), as evidenced by the operating 
profit margin. By utilizing a two-stage OLS model developed by Lev and Sougiannis 
(1996), this study measures the effect of the adoption of the RRMM on operating profit 
margin. The sample includes U.S. firms with significant R&D expenses (a R&D 
expenses/Sales ratio greater than 2%) for the years 2006-2013. Due to the more rapid 
recognition of income using the RRMM, I expect the operating profit margin to be higher 
for those firms adopting the RRMM. The evidence suggests that firms who adopt RRMM 
in the Chemical & Pharmaceutical and Electrical & Electronic R&D industries do 
experience an increase in operating profit margin when compared to firms who do not 
adopt the RRMM. These results are robust in light of the financial crisis.  
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The Revenue Recognition –Milestone Method (Topic 605) 2010 Codification 
amendment affected firms with large Research and Development (R&D) expenses (U.S. 
firms with an R&D expenses/Sales ratio greater than 2%) by allowing earlier revenue 
recognition from projects that meet certain criteria. This paper examined how the RRMM 
affected the Operating Profit Margin (OPM) by using data gathered from Compustat. 
This study covers the year 2006-2013. I expect a significant rise in OPM in the earlier 
years for firms with significance investments in R&D due to the more rapid recognition 
of profit under the RRMM.  
 Before the RMM amendment, there was little authoritative guidance concerning 
revenue recognition on projects that incorporate multiple payment streams for one 
project. The question of when a company can recognize the revenue from these payments 
became a major issue because of this vague authoritative guidance. A form of 
proportional performance milestone revenue recognition was being used before the 
RRMM amendment. However, the legitimacy of this revenue recognition method was 
being questioned due to the little support in authoritative literature. Revenue and the 
timing of its recognition are integral parts of evaluating the profitability of any business. 
“Revenue is almost always the single largest item reported in a company’s income 
statement” (Zhang, 2005). Revenue and the resultant cash flows are also extremely 
important to investors. Investors view trends and growth in reported revenue as an 
indicator of a company’s past and future performance (Zhang, 2005). Generally, based on 
the time value of money, the sooner a company can recognize revenue the better. 
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According to the FASB, revenue cannot be recognized until it is realized or realizable 
and earned (Summers, Sridharan, & McAlum, 2003).  
The timing of revenue recognition in the early years is a problem in industries 
whose projects cover many years. Companies cannot secure credit nor attract investors 
when there is little to no revenue streams during the early years of a project. How soon a 
company can recognize revenue is just as important as the revenue itself. “The timing of 
revenue recognition is important in publicly held companies, especially because of its 
impact on the market valuation of the firm” (Summers, Sridharan, & McAlum, 2003). If a 
company’s growth rate in earnings is raised, investors are more likely to assign a higher 
price to their stocks. More expensive stock earnings will lead to a high market value of 
the company’s shares (Summers, Sridharan, & McAlum, 2003). To alleviate the problem 
of revenue recognition for projects that cover many years, the FASB instituted the 
RRMM, which ties revenue recognition to completion of substantive milestones.  
Firms most affected by the RRMM are those that depend heavily on Research and 
Development (R&D). This is because the projects in the R&D industry can often be 
divided into substantive milestones (Financial Accounting Standards Board of the 
Financial Accounting Foundation, 2010). R&D is characterized by innovation. 
“Innovation is the process that generates goods and services that are of better quality and 
lower prices than their predecessors” (Nord, 2011). Innovation can be classified into two 
distinct classifications. The first is process innovation, which aims to better a productivity 
or process. The second is product innovation, which endeavors to improve current 
products or services or fabricate new products or services (Nord, 2011). As stated by 
Nord, “Firms attempt to innovate by doing research” (Nord, 2011). By meeting 
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substantive milestones and using the RRMM, firms with high R&D expenses are allowed 
to recognize revenue throughout the project, not just in the final year.  
 This study provided empirical evidence on whether or not the 2010 RRMM 
codification amendment has a significant effect on the operating profit margin (OPM) for 
firms with high R&D expense when compared to sales. Prior literature has shown a 
strong correlation of R&D expenditure and positive future cash flow (Cincera & Ravet, 
2010). Boujelben and Fedhila (2011) argue that because R&D investments have a long-
term effect on OPM, and thus, are the most valuable assets in the American economy. 
Therefore, whether or not the RRMM is beneficial to the R&D industry is important to 
the US economy. I add to the literature by being one of the first to examine the effect of 
RRMM on OPM for those firms who are heavily invested in R&D. I find that adoption of 
the RRMM is positively associated with OPM for the firms in the Chemical & 
Pharmaceutical sector (SIC 2800-2899) and Electrical & Electronic (SIC 3600-3699). 
This effect holds in light of the Financial Crisis of 2008-2009. 
  The paper is organized as follows: Section II is a review of prior literature; 
Section III develops the hypothesis; Section IV contains the data and methodology; 
Section V is the result section; Section VI contains a robustness test for the Financial 
Crisis; and Section VII contains the conclusions. 
II. Literature Review 
 R&D projects often include payments upon certain milestones. When these 
milestone events are completed, an entity recognizes the revenue entirely. Previously, 
although there was no Milestone Method in place prior to 2010 when it was adopted by 
the FASB, revenue was being recognized based on milestones in practice. In the absence 
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of authoritative guidance, the milestone recognition process was unregulated and 
milestones were unstandardized. This created variations in revenue recognition practices 
based on milestones prior to 2010. Due to the lack of authoritative guidance concerning a 
Milestone Method, the RRMM amendment has been enacted (Financial Accounting 
Standards Board of the Financial Accounting Foundation, 2010).  
So, whom did the FASB envision would be most affected by the RRMM? R&D 
vendors that provide R&D deliverables where at least one payment is contingent on 
completion of future events, is described by the FASB as those firms most affected by the 
RRMM amendment. This is due to the R&D firm’s ability to easily fulfill milestone 
requirements described by the FASB in the Codification. Furthermore, the FASB decided 
not to expand the scope of the RRMM amendment to industries outside of R&D due the 
possibility of the RRMM amendment inadvertently affecting transactions that were not 
intended to be affected or companies utilizing the RRMM as a revenue management 
technique (Financial Accounting Standards Board of the Financial Accounting 
Foundation, 2010). The FASB’s decision to limit the RRMM only to R&D Industries 
limited the ability of non-R&D industries to use revenue recognition methods to manage 
revenue. 
R&D firms are comprised of a mixture of firms that utilize widely varying 
degrees of R&D in their business practices. This study focuses on the R&D companies in 
various industries rely heavily on R&D (firms where Sales/Revenues > .02) and who 
have the option to use the RRMM. It is important to remember that The RRMM is not 
mandatory or the only acceptable method of revenue recognition for an R&D company 
(Grant Thornton, 2010). Based on Lev and Sougiannis (1996), we separate R&D 
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intensive firms into 6 classifications based on 2-digit SIC codes. These are: Chemical & 
Pharmaceuticals (28); Machinery & Computer Hardware (35); Electrical & Electronic 
(36); Transportation and Vehicles (37); Scientific Instruments (38); and Other 
  Prior literature has examined the effect of R&D on earnings management, 
liquidity and firm value. Altamuro, Beatty and Weber (2002) find evidence of companies 
managing or “smoothing” their earnings through revenue recognition methods. Cincera 
and Ravet (2010) study financing constraints particular to R&D investments. “The main 
finding of this paper is that large European firms are subject to liquidity constraints in the 
financing of their R&D investments, whereas US ones do not appear to be financially 
constrained” (Cincera & Ravet, 2010). Vazquez, Juma’h, Cue and Llorens (2013) study 
how R&D and patents are related to firm performance specific to the Pharmaceutical 
Industry. They use the operative method to assess patent quality and the relationships 
between different patents. “The findings confirm the importance of patents relation to 
firm value and economic performance…” (Vazquez, Juma'h, Cue, & Llorens, 2013). 
Nord (2011) studies the effect on market value that R&D has concerning the 
Pharmaceutical Industry, concluding that the more a firm spends on R&D, the higher the 
market value should be expected. Nord (2011) includes risk as a major factor in decisions 
and relates that investments should be made wisely and free cash flow should be 
respected. Paul, et al. (2010) conducted an analysis concerning R&D productivity 
specific to the Pharmaceutical Industry. They identify the R&D struggles of the 
Pharmaceutical R&D Industry stating, “The pharmaceutical industry is under growing 
pressure from a range of environmental issues” (Paul, et al., 2010). They further offer 
many theories concerning solutions for Pharmaceutical R&D issues including parameters 
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to reduce medication development costs at certain stages of R&D development (Paul, et 
al., 2010).  
Lev and Sougiannis (1996) provide evidence supporting the idea that R&D has 
long-term effects on revenue. This study utilized the Operating Income as an indicator of 
R&D benefits. “Operating income is used as a measure of R&D benefits, since R&D 
investment and its consequences seem largely unrelated to non-operating items, such as 
administrative expenses and financing charges” (Lev & Sougiannis, 1996). Results of 
Lev and Sougiannis’ study show a strong correlation of Stock Price and R&D 
Expenditure (Lev & Sougiannis, 1996). I use Lev and Sougiannis’ definition of R&D 
intensive firms as those firms where R&D expenses/sales are equal to or greater than 2%. 
I use their model that studies the effect of tangible and intangible assets (which includes 
those created by R&D) on operating margins. 
Other prior literature has dealt with the timing issues as they relate to revenue 
recognition. The timing of revenue recognition is vital. When companies recognize 
revenue too early, artificially inflating revenue and earnings per share, it gives the 
company a temporary boost in the stock market, but later causes companies’ standings to 
plummet because elevated revenue levels cannot be maintained. The artificially inflated 
revenues and earnings can lead to a false sense of security for investors because unstated 
losses may follow. In the case of Micro Strategy, the early recognition of revenue over 
inflated their revenues and caused the company to not report incurring losses. Micro 
Strategy was disciplined for its unlawful, misappropriated revenue. They had to restate 
their financial statements for the previous years, pay fines to the SEC for account fraud, 
issue a public apology and certain employees’ professional licenses were revoked. Even 
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after all this, Micro Strategy’s stock price fell drastically and the company earned a 
reputation of unethical and a “bad” company (Summers, Sridharan, & McAlum, 2003). 
According to Zhang (2005), “I find early recognition yields more timely revenue 
information, as evidenced by higher contemporaneous correlation with information 
impounded in stock returns.” Zhang (2005) also finds in his study that this early revenue 
recognition diminishes future cash flow realizations and time-series predictability of 
reported revenue. Then, there is the pressure that the market places on managers to meet 
or beat earnings forecasts. According to Summers, Sridharan, and McAlum (2003), the 
pressures by stockholders and increasing competition have encouraged the recognition of 
revenue before it is proper. I add to the literature in this area because I look at the effect 
of RRMM, a standard that codifies the timing of revenue recognition based on 
milestones, thereby causing earlier recognition of revenues for R&D firms. 
 Prior to the codification of revenue recognition methods for the R&D industry, 
revenue was recognized using best practices, which led to uncertainty due to the various 
methods, employed by firms. Srivastava’s study (2008) focuses on the optimal level of 
objectivity and verifiability. Srivastava (2008) argues that conservative standards affect 
revenue relevance and lax standards affect revenue reliability. Srivastava (2008) finds 
that highly objective standards reduce the software firms’ earnings information relevance 
by deferring revenues because of multiple-element contracts. Altamuro, Beatty and 
Weber (2002) find that some firms were using revenue recognition methods to manage 
their earnings in an improper way. They found that restarting firms were less likely to 
miss earnings targets, have more incentives to manage earnings and have less auditor 
evaluations. They also found a reduction in the association of future cash flows and 
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earnings for restarting firms after the implementation of SAB 101. Overall, Altamuro 
Beatty and Weber (2002) conclude that SAB 101 did not improve the quality of earnings 
for restating first and the firms can still manage their earnings through other revenue 
recognition methods  
Huefner and Largay (2008) report on the importance of revenue management. 
Huefner and Largay (2008) find that Revenue Management (RM) proves more valuable 
in the future than Cost Management and yields a better bottom line. Their studies show 
RM has been most successful in industries with high operating leverage. High operating 
leverage is a result of high fixed cost (costs that do not change no matter how much the 
company sells) and low variable cost (costs dependent on how much the company sells). 
Huefner and Largay believe that RM may apply in more of today’s business settings 
(Huefner & Largay III, 2008). I add to the literature by studying the effect of verifiability 
that has been introduced to the revenue recognition for firms in the R&D industry by 
RRMM.  
III. Hypothesis Development 
The increase in recognized revenue resulting from the completion of a milestone 
will raise the Operating Income (OI) on the Income Statement thus raising the Net 
Income (NI) on the Income statement and the Retained Earnings (RE) on the Statement 
of Retained Earnings and the Balance Sheet. The decrease in liability, unearned revenues, 
will lower the liability stated on the Balance Sheet. This raise in revenue/sales and 
decrease in liabilities will reflect in the Operating Profit Margin. The Operating Profit 
Margin (OPM) is defined as: 
Operating Profit Margin =  Operating Income 
       Net Sales 
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The OI represents the income from normal day-to-day operations. The net sales represent 
all the sales minus any discounts, allowances for damages or theft, or deductions 
concerning returns. Thus, the OPM results in a percentage that is the portion of each 
dollar earned that is profit before interest and taxes. The OPM is an indicator of 
company’s operating efficiency.  
Hsu, Chen, Chen and Wang (2013) conducted a study testing the relationship 
between R&D expenditure and financial indicators that included returns, net sales and 
operational performance. According to Hsu, Chen, Chen and Wang (2013), R&D 
expenditures lower operating income. Hsu, Chen, Chen and Wang (2013) relate this 
theory to the fact R&D expenses are considered operating expenses. Their study states, 
“Though R&D activity increases net sales, increased operating costs finally result in 
reduced operating income” (Hsu, Chen, Chen, & Wang, 2013). Hsu, Chen, Chen and 
Wang (2013) further related this outcome to a lagging R&D contribution stating, “…the 
contribution of R&D activity to operating income may not materialize for quite some 
time.” This is in agreement with the findings of Sougiannis (1996) and Dugan, 
McEldowney, Turner and Wheatley (2014) that the indirect effect of R&D (the effect of 
one dollar of R&D expense on subsequent years’ operating income) is much greater than 
its direct effect (the effect of one dollar of R&D expense in the current year). 
Recognizing revenue in the early years of a project as a firm meets certain 
milestones gives investors a more accurate view of a company’s health, its ability to 
generate cash flows. In addition, creditors can get a clearer picture of a firm’s 
creditworthiness based on more timely recognition of revenues. Therefore, since the 
RRMM allows for earlier recognition of revenues based on an R&D firm meeting 
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milestones, I expect to find a positive association between those firms that utilize the 
RRMM and operating profit margin when compared to R&D firms who are not using the 
RRMM.  
My first empirical hypothesis (in the alternative form) is: 
H1—Firms who rely heavily on R&D and who elect to use the Revenue 
Recognition Milestone Method (RRMM) will experience a rise in operating profit margin 
when compared to R&D firms who do not use the RRMM. 
IV. Data and Methodology 
Data was collected from Compustat on U.S. firms with an R&D expenses/Sales 
ratio greater than 2% (firms with significant R&D expenses). This study covers the years 
2006-2013. All companies that do not originally operate and report in the USA were 
removed, eliminating 7960 observations. Since 2007, foreign public issuers who report 
their financial statements using IFRS (the European Union, for example) do not have to 
reconcile their statements to U.S. GAAP. Since the IASB allows capitalization of 
development costs and U.S .GAAP does not, it is difficult to determine if any rise in 
OPM is due solely to the use of the RRMM. Next, companies in the financial services 
industry were removed (SIC codes: 5000-5999) which resulted in the removal of. 3392 
observations. Prior studies have shown that firms in the financial sector operate 
significantly different from the rest of the market. I then removed companies that do not 
have financial statements in December were removed. This is necessary to maintain that 
the timing for the use of the RRMM is consistent. Another 13438 observations were 
removed. Next, observations that did not have OI were removed (16765) and 
observations with Sale numbers of 0 were dropped (2).  
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As described by Lev and Sougiannis (1996), I define R&D firms as companies 
with R&D/Net Sales greater than 2%. Another 15,152 observations were removed. 
Observations that were missing Total Asset and Property, Plant and Equipment amounts 
were removed. Observations that were missing Inventory, Goodwill, Advertising 
Expense and Investment in Unconsolidated Subsidiaries were not removed, but replaced 
with the number 0. In checking a random sample of the firms with missing values for 
these variables, I discovered that the values were not missing values but were caused 
because the firm did not engage in these activities and were still be actively in business. I 
hand-collected information on the method of revenue recognition method and removed 
any firms who did not clearly indicate which method they were using (elimination of 
another 75 observations). This leaves me with a sample of 3,208 firm years. 
 
Table 1: Firm Years 












Based on Lev and Sougiannis (1996), the firms were separated into two-digit SIC 
codes which are historically distinct in their use of R&D. Table 2 shows the 6 categories 
with SIC 99 being assigned to all firms who were not in the other 5 2-digit SIC codes.  
 
Table 2: Lev and Sougiannis 2 Digit SIC Code Industry Groups 
 
R&D Industry 2 Digit SIC code 
Chemical & Pharmaceuticals 28  
Machinery & Computer Hardware 35  
Electrical & Electronic 36  
Transportation Vehicles 37  
Scientific Instruments 38  
Other R&D Industries 99  
 
Because it is expected that operating income will rise as more is spent on R&D, as 
per Lev and Sougiannis (1996) (LS), I perform a two-stage OLS regression. LS define 
Industry R&D Expense (IRD) as: 
(1) IRD = Total R&D Expense for 2 digit SIC – R&D Expense for a Company 
Total Sales Industry – Sales for the Company    
 
The IRD value was utilized to create the fitted values. The regression was run separately 
for each 2-digit SIC code (6 times in total). 
   (2) OIt = α0t + α1t IRD + εt         
LS then utilize the formula that operating income is dependent on tangible and intangible 
assets. 
   (3) OIt = (TA, IA)          
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where TA (tangible assets ) are defined as goodwill, total assets, inventory, investment in 
unconsolidated subsidiaries, property, plant and equipment and IA (intangible assets ) is 
defined as R&D expenses and advertising expenses. All variable are scaled by sales. I 
then Add the effect of the RRMM, which is 1 if a company is using the RRMM and) 
otherwise. My model is: 
   OIt = α0 + α1 ADt + α2 RDt + α3 Tangiblet + α4 RRMMt + εt 
  
OI: Operating income without the effects of R&D and advertising 
expenses scaled by sales 
AD:  Advertising expenses scaled by sales 
RD:  Fitted values of RD scaled by sales 
Tangible: Goodwill, total assets, inventory, investment in unconsolidated 
subsidiaries, property, plant and equipment scaled by sales 
RRMM: 1 if company is using the Revenue Recognition – Milestone 
Method; 0, otherwise. 
Because the behavior of these companies is observed across time, I employ a 
panel data regression. Using a Hausman test, my results indicate a fixed effect model is 
appropriate and that time-fixed effects are necessary. A fixed effects model eliminates the 
need for industry indicators and other time-invariant variables. Next, I test for 
heteroskedasticity and serial correlation (using a Wald and Woolridge test, respectively). 
The model suffers from both, which is common with panel data and I correct for both by 




 The tables below show the descriptive statistics  
Table 3: Industry by 2-Digit SIC Codes 
 
R&D Industry 2 Digit SIC code # of firms  
Chemical & Pharmaceuticals 28 533 
Machinery & Computer Hardware 35 323 
Electrical & Electronic 36 529 
Transportation Vehicles 37 210 
Scientific Instruments 38 565 
Other R&D Industries 99 1048 
 Total 3208 
 




Total 0 1 Percentage 
Adopted RRMM 
28 385 148 27.8% 533 
35 305 18 5.6% 323 
36 480 49 9.3% 529 
37 193 17 8.1% 210 
38 507 58 10.3% 565 
99 970 78 7.4% 1048 




Table 5: Descriptive Statistics 
 
Variable # of Firms Mean St. Dev. Minimum Maximum 
OI 3208 0.259 0.155 0.043 0.810 
RD 3208 0.108 0.105 0.020 1.185 
AD 3208 0.013 0.032 0 .201 
Tangible 3208 1.929 1.000 0.327 6.700 
RRMM* 3208 0.115 0.319 0 1 
 
* # of firm years using RRMM = 368; # of firm years not using RRMM = 2,840 
 
where 
OI: Operating income without the effects of R&D and advertising 
expenses scaled by sales 
RD:  Fitted values of RD scaled by sales 
AD:  Advertising expenses scaled by sales 
Tangible: Goodwill, total assets, inventory, investment in unconsolidated 
subsidiaries, property, plant and equipment scaled by sales 
RRMM: 1 if company is using the Revenue Recognition – Milestone 
Method; 0, otherwise. 
As per LS, I then ran a FE regression for each 2-digit SIC codes. The results of 
these regression tests are shown below for each two-digit SIC code and variable.  
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Table 6: Regression Results (N = 3208) Years: 2007-2011 
 
OIt = α0 + α1 ADt + α2 RDt + α3 Tangiblet + α4 RRMMt + εt 
 
 
Variable SIC 28 SIC 35 SIC 36 SIC 37 SIC 38 SIC 99 
Constant 0.262*** 0.092*** 0.129*** 0.095*** 0.153*** 0.193*** 
ADt  0.767* 2.287*** 1.587*** 0.556 1.322*** 1.058*** 
RDt 0.0008*** -0.001*** -0.0001 -0.0007 0.0004 0.0007 
Tangiblet 0.020** 0.055*** 0.047*** 0.028*** 0.034*** 0.028*** 
RRMMt 0.198*** -0.006 0.060** -0.016 0.012 -0.013 
N 533 323 529 210 565 1048 
Within R2 0.1478 0.1979 0.1217 0.0849 0.0823 0.1949 
Between R2 0.4435 0.0063 0.0380 0.1477 0.0002 0.1673 
Overall R2 0.1418 0.1919 0.1200 0.0763 0.0811 0.1946 
 
*, **, *** Significance at the 0.01, 0.05 and 0.10 respectively 
 
where 
OI: Operating income without the effects of R&D and advertising 
expenses scaled by sales 
RD:  Fitted values of RD scaled by sales 
AD:  Advertising expenses scaled by sales 
Tangible: Goodwill, total assets, inventory, investment in unconsolidated 
subsidiaries, property, plant and equipment scaled by sales 
RRMM: 1 if company is using the Revenue Recognition – Milestone 
Method; 0, otherwise. 
As expected, the data suggest that advertising expenses are positively significant 
for all industries but the Transportation Vehicles, where it is not statistically different 
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from 0. Most industries experience large increases (77%-229%), indicating that 
advertising has a very significant economic impact on profit margins. R&D expenses 
have a much smaller impact and are only statistically significant for Chemical and 
pharmaceutical (SIC 28) and Machinery & computer hardware (SIC 35). This may be 
because there has not been enough time for the R&D to benefit OPM due to the lag in 
benefit form R&D described by Lev and Sougiannis (1996). Tangible assets have a 
statistically significant positive relationship with OPM for all industries. This is because 
expenditures on such assets should generally add direct value to the business. If they do 
not, then there is no reason for the expenditure. These results are consistent with prior 
research. 
Next, I examine my variable of interest, RRMM. The results suggest that the 
Chemical & Pharmaceutical and the Electronical & Electronic R&D industries are 
positively associated with RRMM: i.e. firms who adopt the RRMM have higher OPM 
when compared to other R&D firms who do not employ the RRMM, all else equal. As 
for the other industries, there is not enough evidence to suggest that employing the 
RRMM has any impact on OPM. This provides empirical evidence the RRMM generally 
benefitted these two industries and not the others. Given that the Chemical & 
Pharmaceutical industry had the highest percentile of changing to the RRMM when it 
became available, the statistically significant association with OPM is not surprising. In 
the case of the Electrical & Electronic industry, given a relatively low percentage of the 
companies switched to the RRMM after 2010, the data still suggests a positive significant 
effect on OPM. This industry is often poised on the cutting edge of the fast-moving 
technology revolution so this result is once again not surprising. Overall, this means that 
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for these two industries, the RRMM was significantly different from their previous 
revenue recognition method concerning R&D. If the adoption of the RRMM did not 
represent a significant change in revenue recognition for the other industries (i.e. they 
were utilizing a similar method previously). This explains why the other industries were 
not significantly impacted by the adoption of the RRMM.  
VI. Robustness Test- the Financial Crisis of 2008-2009 
The U.S. experienced the financial crisis caused in large part by subprime 
mortgages. According to the National Bureau of Economic research, the financial crisis 
lasted from December 2007 and ended in June 2009. The effect of the Financial Crisis of 
2008-2009 was a macro economic effect that affected all R&D firms. It is very difficult, 
if not impossible, to halt R&D projects due to current economic problems. The RRMM 
was put in place in 2010, a period in which the economy was beginning to recover from 
the Financial Crisis. Based on these facts, I expect the Financial Crisis will have little to 
no effect on R&D firms. My second empirical hypothesis (in the alternate form) 
H2—Firms who rely heavily on R&D and who elect to use the Revenue 
Recognition Milestone Method (RRMM) will experience a rise in operating profit margin 
when compared to R&D firms who do not use the RRMM in spite of the Financial Crisis. 
I test this hypothesis by removing the years 2008-2009 from the data. I expect the 
effect of RRMM to be similar to the results achieved when the years of the financial 
crisis are included. The results are in Table 7. 
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Table 7: Regression Results (N = 2486) without Financial Crisis 
 
OIt = α0 + α1 ADt + α2 RDt + α3 Tangiblet + α4 RRMMt + εt 
 
 
Variable SIC 28 SIC 35 SIC 36 SIC 37 SIC 38 SIC 99 
Constant 0.254*** 0.105*** 0.125*** 0.099*** 0.147*** 0.193*** 
ADt  0.683 2.535*** 1.470** 0.341 1.567*** 1.021*** 
RDt 0.0007** -0.001 -0.0001 -0.002 0.00001 0.0004 
Tangiblet 0.018 0.051*** 0.050*** 0.030*** 0.038*** 0.028*** 
RRMMt 0.197*** -0.003 0.058*** -0.0187 0.014 -0.013 
N 405 253 414 160 443 811 
Within R2 0.1813 0.1789 0.1454 0.0958 0.1005 0.1907 
Between R2 0.6258 0.3791 0.1004 0.3409 0.0010 0.0179 
Overall R2 0.1879 0.1795 0.1405 0.0966 0.0989 0.1902 
 
*, **, *** Significance at the 0.01, 0.05 and 0.10 respectively 
 
where 
OI: Operating income without the effects of R&D and advertising 
expenses scaled by sales 
RD:  Fitted values of RD scaled by sales 
AD:  Advertising expenses scaled by sales 
Tangible: Goodwill, total assets, inventory, investment in unconsolidated 
subsidiaries, property, plant and equipment scaled by sales 
RRMM: 1 if company is using the Revenue Recognition – Milestone 
Method; 0, otherwise. 
With the exception of advertising expenses, the results with the financial crisis do 
not differ much from those without the financial crisis. For Chemical and 
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Pharmaceuticals and Transportation Vehicles, advertising expenses do not appear to have 
an impact on OPM when the financial crisis is excluded. The variable of interest, 
RRMM, has no statistically significant change when the years of the Financial Crisis is 
eliminated. I conclude there is not enough evidence to suggest that the Financial Crisis of 
2008-2009 is not driving the results of the association between RRMM and OPM 
VII. Conclusion  
 In conclusion, this paper examines the effect of the Revenue Recognition – 
Milestone Method (RRMM) that the FASB approved in 2010 to aid R&D in clarifying 
revenue recognition. Prior to the adoption of the RRMM, revenue recognition was not 
clearly defined for R&D firms. RRMM codifies revenue recognition for R&D firms only. 
The FASB wanted R&D firms to be able to recognize revenue as certain milestones were 
achieved. Its purpose was to clarify when R&D firms could recognize revenue from the 
earnings process. Earlier recognition allows R&D firms to give a clearer picture of the 
health of firms, improving stock prices and creditworthiness. By utilizing a two-stage 
OLS model developed by Lev and Sougiannis (1996), this study measures the effect of 
the adoption of the RRMM on operating profit margin. The sample includes U.S. firms 
with significant R&D expenses (a R&D expenses/Sales ratio greater than 2%) for the 
years 2006-2013. Due to the more rapid recognition of income using the RRMM, the 
evidence suggests that firms who adopt RRMM in the Chemical & Pharmaceutical and 
Electrical & Electronic R&D industries do experience an increase in operating profit 
margin when compared to firms who do not adopt the RRMM. These results are robust in 
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